CAMBRIDGE, MA, Amylyx Pharmaceuticals today announced the closing of an oversubscribed $135 million Series C financing.
Amylyx Pharmaceuticals today announced the closing of an oversubscribed $135 million Series C financing, led by Viking Global Investors, to support the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative diseases.
The financing included participation from Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, Marshall Wace, Tybourne Capital Management, Verition Fund Management, aMoon Fund and Falcon Edge. Existing investors, including Morningside Ventures, 683 Capital Management, Belinda Termeer and Polaris Founders Capital, also participated in the financing.
Amylyx Pharmaceuticals is a pharmaceutical company working on developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and other neurodegenerative diseases.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about